低剂量与高剂量4因子前列红素复合物缩剂在XA因子抑制剂相关出血中的作用:一种定性系统性审查
Anna Phillips1, Colby Bradley1, Julie Cash1
1Presbyterian College School of Pharmacy, Clinton, SC, USA.
概括
低剂量与高剂量的四因子原素复合缩物 (4F-PCC) 在治疗XA抑制因子出血时表现出类似的有效性和安全性. 需要进一步的前性研究来证实这些关于静血疗效的发现.
科学领域:
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
- 临床医学 临床医学
背景情况:
- Xa因子抑制剂是广泛使用的抗凝固剂.
- 与Xa因子抑制剂相关的出血并发症构成了重大的临床挑战.
- 四因子前激素复合缩物 (4F-PCC) 是这些出血的潜在逆转剂.
研究的目的:
- 评估当前关于使用4F-PCC治疗XA因子抑制剂相关出血的文献.
- 为了比较低剂量与高剂量4F-PCC的静血疗效和安全性.
- 评估结果,如静血疗效,医院死亡率和静脉血栓栓塞.
主要方法:
- 在PubMed和EBSCOhost.host上进行了系统的文献搜索.
- 研究包括患有因子Xa抑制剂出血的患者,这些患者接受了低剂量或高剂量的4F-PCC治疗.
- 排除标准包括替代逆转药物 (例如新鲜冷血,安德克萨内特α) 和没有比较组的研究.
- 静血疗效是主要的研究结果.
主要成果:
- 四项研究符合审查的纳入标准.
- 在低剂量和高剂量4F-PCC队列中观察到类似的静血疗效率.
- 在两个剂量组中,医院死亡率和静脉血栓塞栓症的比较率都相似.
结论:
- 低剂量和高剂量的4F-PCC似乎在管理与Xa因子抑制剂相关的出血时具有类似的临床有效性和安全性.
- 这些发现表明,无论4F-PCC的剂量如何,可能会产生类似的结果.
- 建议在未来进行前性研究,以验证这些观察并确认临床影响.
相关概念视频
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
696
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
696
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.6K
01:24Disorders of Hemostasis
904
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
904
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
523
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
523
01:16Clot Retraction and Fibrinolysis
5.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.9K